Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Pediatric | 15 | 2018 | 73 | 2.900 |
Why?
|
| Erythrocyte Transfusion | 16 | 2022 | 72 | 2.730 |
Why?
|
| Anemia | 14 | 2022 | 126 | 1.790 |
Why?
|
| High-Frequency Ventilation | 4 | 2016 | 5 | 1.720 |
Why?
|
| Critical Illness | 18 | 2022 | 321 | 1.700 |
Why?
|
| Respiratory Insufficiency | 4 | 2018 | 154 | 1.140 |
Why?
|
| Child | 29 | 2023 | 4436 | 1.070 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 58 | 0.820 |
Why?
|
| Hospice Care | 1 | 2023 | 65 | 0.800 |
Why?
|
| Hospitalization | 3 | 2017 | 1344 | 0.800 |
Why?
|
| Palliative Care | 1 | 2023 | 226 | 0.730 |
Why?
|
| Evidence-Based Medicine | 13 | 2022 | 458 | 0.720 |
Why?
|
| Respiration, Artificial | 4 | 2016 | 295 | 0.670 |
Why?
|
| Isoflurane | 2 | 2012 | 16 | 0.660 |
Why?
|
| Anesthetics, Inhalation | 2 | 2012 | 18 | 0.650 |
Why?
|
| Critical Care | 15 | 2022 | 389 | 0.600 |
Why?
|
| Hemoglobins | 3 | 2018 | 135 | 0.590 |
Why?
|
| Child, Preschool | 13 | 2018 | 1932 | 0.580 |
Why?
|
| Hemorrhage | 4 | 2022 | 266 | 0.550 |
Why?
|
| Infant | 11 | 2022 | 1594 | 0.520 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2016 | 12 | 0.510 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 144 | 0.480 |
Why?
|
| Hypoxia | 1 | 2016 | 113 | 0.470 |
Why?
|
| Antidotes | 1 | 2014 | 21 | 0.440 |
Why?
|
| Poisoning | 1 | 2014 | 32 | 0.440 |
Why?
|
| Attitude to Death | 1 | 2012 | 16 | 0.400 |
Why?
|
| Group Processes | 1 | 2012 | 43 | 0.390 |
Why?
|
| Bronchial Spasm | 1 | 2012 | 8 | 0.390 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 57 | 0.390 |
Why?
|
| Humans | 35 | 2023 | 62653 | 0.380 |
Why?
|
| Phlebotomy | 1 | 2012 | 7 | 0.380 |
Why?
|
| Naloxone | 1 | 2011 | 60 | 0.340 |
Why?
|
| Narcotic Antagonists | 1 | 2011 | 135 | 0.320 |
Why?
|
| Environmental Exposure | 1 | 2011 | 219 | 0.310 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2018 | 16 | 0.300 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 707 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 725 | 0.290 |
Why?
|
| Infant, Newborn | 7 | 2018 | 1338 | 0.290 |
Why?
|
| Buprenorphine | 1 | 2011 | 190 | 0.280 |
Why?
|
| Athetosis | 1 | 2007 | 2 | 0.270 |
Why?
|
| Atracurium | 1 | 2007 | 2 | 0.270 |
Why?
|
| Status Asthmaticus | 1 | 2007 | 6 | 0.270 |
Why?
|
| Chorea | 1 | 2007 | 10 | 0.270 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2007 | 13 | 0.270 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2007 | 122 | 0.240 |
Why?
|
| Adolescent | 7 | 2018 | 6165 | 0.240 |
Why?
|
| Internship and Residency | 1 | 2012 | 787 | 0.230 |
Why?
|
| Age Distribution | 2 | 2014 | 258 | 0.200 |
Why?
|
| Community Health Services | 1 | 2023 | 127 | 0.200 |
Why?
|
| New England | 2 | 2014 | 272 | 0.190 |
Why?
|
| Transfusion Reaction | 2 | 2018 | 46 | 0.180 |
Why?
|
| Male | 10 | 2016 | 29472 | 0.180 |
Why?
|
| Tay-Sachs Disease | 1 | 2022 | 45 | 0.180 |
Why?
|
| Liquid Ventilation | 1 | 2001 | 4 | 0.180 |
Why?
|
| Supine Position | 1 | 2001 | 32 | 0.180 |
Why?
|
| Prone Position | 1 | 2001 | 28 | 0.180 |
Why?
|
| Fluoroscopy | 1 | 2001 | 64 | 0.180 |
Why?
|
| Pain | 1 | 2023 | 406 | 0.170 |
Why?
|
| Fluorocarbons | 1 | 2001 | 38 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2001 | 118 | 0.170 |
Why?
|
| Blood Specimen Collection | 2 | 2012 | 20 | 0.170 |
Why?
|
| Female | 9 | 2016 | 32478 | 0.160 |
Why?
|
| Thalassemia | 1 | 2018 | 4 | 0.150 |
Why?
|
| Anemia, Hemolytic | 1 | 2018 | 12 | 0.150 |
Why?
|
| Shock, Hemorrhagic | 1 | 2018 | 19 | 0.150 |
Why?
|
| Shock | 1 | 2018 | 33 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 24 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 62 | 0.140 |
Why?
|
| Length of Stay | 2 | 2014 | 804 | 0.140 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2017 | 15 | 0.140 |
Why?
|
| Health Personnel | 1 | 2021 | 363 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2018 | 158 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 110 | 0.140 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 100 | 0.140 |
Why?
|
| Patient Care | 1 | 2017 | 80 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2016 | 3258 | 0.130 |
Why?
|
| Splenic Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
|
| Quality of Life | 1 | 2023 | 1221 | 0.130 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 142 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2014 | 6528 | 0.130 |
Why?
|
| Time Factors | 3 | 2016 | 3740 | 0.120 |
Why?
|
| Propensity Score | 1 | 2016 | 154 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 111 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 145 | 0.110 |
Why?
|
| Sepsis | 1 | 2018 | 279 | 0.110 |
Why?
|
| Erythrocyte Count | 3 | 2018 | 15 | 0.110 |
Why?
|
| Accidents | 1 | 2014 | 14 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2012 | 2039 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 726 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 238 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2016 | 768 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 2173 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 294 | 0.100 |
Why?
|
| Suicide, Attempted | 1 | 2014 | 106 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2016 | 405 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 339 | 0.100 |
Why?
|
| Risk Factors | 3 | 2012 | 5302 | 0.100 |
Why?
|
| Terminally Ill | 1 | 2012 | 16 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 445 | 0.100 |
Why?
|
| Platelet Transfusion | 2 | 2022 | 11 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 316 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 729 | 0.100 |
Why?
|
| Drug Overdose | 1 | 2014 | 130 | 0.090 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 50 | 0.090 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 187 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 221 | 0.090 |
Why?
|
| Canada | 2 | 2010 | 154 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 252 | 0.090 |
Why?
|
| Drug Storage | 1 | 2011 | 22 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 409 | 0.090 |
Why?
|
| Medical Audit | 1 | 2011 | 60 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2014 | 355 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1540 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 455 | 0.090 |
Why?
|
| Blood Gas Analysis | 2 | 2018 | 34 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2011 | 365 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 658 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2010 | 148 | 0.080 |
Why?
|
| Patient Safety | 1 | 2012 | 242 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5587 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 1350 | 0.070 |
Why?
|
| Incidence | 1 | 2012 | 1367 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 160 | 0.070 |
Why?
|
| Ventilator Weaning | 1 | 2007 | 20 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2012 | 2537 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2646 | 0.060 |
Why?
|
| Blood Component Transfusion | 1 | 2022 | 10 | 0.050 |
Why?
|
| Plasma | 1 | 2022 | 37 | 0.050 |
Why?
|
| Young Adult | 1 | 2012 | 4633 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2022 | 107 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2001 | 18 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 2445 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2001 | 43 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2001 | 63 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 2001 | 54 | 0.040 |
Why?
|
| Random Allocation | 1 | 2001 | 197 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2001 | 97 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2001 | 293 | 0.040 |
Why?
|
| Ventilators, Mechanical | 1 | 2000 | 30 | 0.040 |
Why?
|
| Lung Injury | 1 | 2000 | 33 | 0.040 |
Why?
|
| Swine | 1 | 2001 | 368 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2001 | 242 | 0.040 |
Why?
|
| IgA Deficiency | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2018 | 8 | 0.040 |
Why?
|
| Vital Signs | 1 | 2018 | 11 | 0.040 |
Why?
|
| United States | 2 | 2010 | 7718 | 0.040 |
Why?
|
| Decision Trees | 1 | 2018 | 51 | 0.040 |
Why?
|
| Acute Disease | 1 | 2000 | 670 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 78 | 0.040 |
Why?
|
| Survival Rate | 1 | 2000 | 839 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 225 | 0.030 |
Why?
|
| Animals | 3 | 2016 | 20579 | 0.030 |
Why?
|
| Albumins | 1 | 2016 | 35 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2016 | 42 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 271 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2016 | 100 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 189 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 200 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 140 | 0.030 |
Why?
|
| Dependovirus | 1 | 2022 | 694 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 168 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2022 | 770 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 302 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 377 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1554 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 981 | 0.020 |
Why?
|
| Materials Management, Hospital | 1 | 2010 | 2 | 0.020 |
Why?
|
| Adult | 1 | 2000 | 16623 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 10802 | 0.010 |
Why?
|